Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Inthepezon Aug 19, 2021 2:21pm
140 Views
Post# 33733921

RE:Lol

RE:LolIt’s because you are tra$h.

Rarbar99 aka Yukonjizz face greatest hits that have been debunked in the AGM:

-“Today's report was the final nail in the coffin”
-“its over. It's not speculation. If the company knew this was all fudd and an overreaction”
-“5x liver transaminase levels is VERY DANGEROUS. This is not a small side-effect or a bad reaction, this is very serious and there is no way it's just an "outlier" that can be brushed off.”

and people call him out on his BS, his response is: 

-And just so y'all know, I'm not a short. I only discovered this company after it crashed and I own 25,000 shares at average price of $1.07


LOL. This Yukonjizz face down to the same recycled defence. 

Rarbar99 wrote: I'm done replying to Inthepez, just check his profile this kids been talking trash to bears for several months. Even after this dropped 70% he still refuses to listen to criticism and calls everything "fud"

fact of the matter is that this is in very bad shape. The volume is already gone, everything from here is unpredictable. It's just as likely to go to $0.75 as it is $1.50.


<< Previous
Bullboard Posts
Next >>